Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - atovaquonum,proguanili hydrochloridum - tabletti, kalvopäällysteinen - 62.5 mg / 25 mg - proguaniili, yhdistelmävalmisteet

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - atovaquonum,proguanili hydrochloridum - tabletti, kalvopäällysteinen - 250 mg / 100 mg - proguaniili, yhdistelmävalmisteet

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

glenmark arzneimittel gmbh - proguanili hydrochloridum,atovaquonum - tabletti, kalvopäällysteinen - 250 mg / 100 mg - proguaniili, yhdistelmävalmisteet

Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastiset aineet - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq monoterapiana on tarkoitettu aikuisille potilaille, joilla on paikallisesti pitkälle edennyt tai metastaattinen ei-pienisoluinen keuhkosyöpä aikaisemman kemoterapian jälkeen. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq monoterapiana on tarkoitettu aikuisille potilaille, joilla on paikallisesti pitkälle edennyt tai metastaattinen ei-pienisoluinen keuhkosyöpä aikaisemman kemoterapian jälkeen. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

glenmark arzneimittel gmbh - atovaquone - oraalisuspensio - 150 mg/ml - atovakoni

Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

hra pharma rare diseases - mitotaanin - adrenal cortex neoplasms - antineoplastiset aineet - kehittyneiden (tarttumattomien, metastaattisten tai relapsoitujen) lisämunuaisen kortikaalisen karsinooman oireenmukainen hoito. lysodrenin vaikutusta ei-toiminnalliset lisämunuaisen kuorikerroksen karsinooman hoidossa ei ole osoitettu.

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

novartis finland oy - ciclosporin - infuusiokonsentraatti, liuosta varten - 50 mg/ml - siklosporiini

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - fosaprepitant dimeglumine - infuusiokuiva-aine, liuosta varten - 150 mg - aprepitantti

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

ebewe pharma ges.m.b.h. nfg.kg - cisplatin - infuusiokonsentraatti, liuosta varten - 1 mg/ml - sisplatiini

Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - palifermiinia - mukosiitti - kaikki muut terapeuttiset tuotteet - kepivance on ilmoitettu vähentävän esiintyvyys, kestoa ja vakavuutta mukosiitin aikuisilla hematologisia pahanlaatuisia saa myeloablative radiochemotherapy liittyy vakavia mukosiitti yleisyys ja vaativat autologinen verta-stem cell tuki.